Il punto su
Linfoma di Burkitt in età pediatrica
Burkitt lymphoma in Paediatrics
Fabio Timeus1,2, Matilde Piglione2, Franca Fagioli2, Aldo Ravaglia3
1UOC di Pediatria e Neonatologia, Ospedale di Chivasso, ASL TO4, Torino
2Onco-Ematologia Pediatrica, Centro Trapianti e Terapia Cellulare, Ospedale Infantile “Regina Margherita”, Torino
3Pediatra di famiglia, Chivasso (Torino)
Giugno 2021 | DOI: 10.53126/MEBXXIV175
Abstract
Sporadic Burkitt lymphoma (BL) accounts for about 80% of non-Hodgkin lymphomas in childhood and adolescence, with an incidence of 3-5 cases per million in developed countries. The hallmark of LB is the deregulation of MYC oncogene, usually caused by the [t(8;14)(q24;q32)] translocation, involving the gene of immunoglobulin heavy chain. BL is a very aggressive neoplasm, with a doubling time of 12-24 hours and its diagnosis and therapy are a true haematologic emergency. Abdomen, head and neck are the most frequent sites of presentation and the involvement of ileo-caecal area can cause an intussusception as first manifestation of the disease.
BL and mature B-cell acute leukaemia (the leukaemic manifestation of BL) share the same therapeutic approach, intensive short courses with multiple alternating chemotherapy agents, the use of high dose-methotrexate and intrathecal CNS prophylaxis. The outcomes are satisfactory: in Italy during the period 1997-2014 the children with BL were treated according to the AIEOP LNH-97 protocol, achieving more than 90% of 5 year-survival.
In the last decades, the prognosis for children and adolescents with cancer has dramatically improved and the increasing number of long-term survivors has focused the attention of clinicians on the late effects of cancer and its therapy. A multidisciplinary follow up and a correct transition from the paediatrician to the primary care doctor plays a central role not only in the early detection and therapy of late effects of cancer but also in supporting the patient to realize their physical, mental and social well-being as much as possible.
BL and mature B-cell acute leukaemia (the leukaemic manifestation of BL) share the same therapeutic approach, intensive short courses with multiple alternating chemotherapy agents, the use of high dose-methotrexate and intrathecal CNS prophylaxis. The outcomes are satisfactory: in Italy during the period 1997-2014 the children with BL were treated according to the AIEOP LNH-97 protocol, achieving more than 90% of 5 year-survival.
In the last decades, the prognosis for children and adolescents with cancer has dramatically improved and the increasing number of long-term survivors has focused the attention of clinicians on the late effects of cancer and its therapy. A multidisciplinary follow up and a correct transition from the paediatrician to the primary care doctor plays a central role not only in the early detection and therapy of late effects of cancer but also in supporting the patient to realize their physical, mental and social well-being as much as possible.
Contenuto riservato
Per leggere l'articolo è necessario effettuare il login.
Per l'acquisto del singolo articolo scrivi a
abbonamenti@medicoebambino.com
(la mail si prepara da sola con gli estremi dell'articolo);
se accedi, la richiesta parte con un click.
Classificazione MeSH
Bibliografia
- Burkitt D. A sarcoma involving the jaws in African children. Br J Surg 1958;46(197):218-23. DOI: 10.1002/bjs.18004619704.
- Dunleavy K, Little RF, Wilson WH. Update on Burkitt lymphoma. Hematol Oncol Clin N Am 2016;30:1333-43. DOI: 10.1016/j.hoc.2016.07.009.
- Swerdlow SH, Campo E, Harris NL, et al. (eds). WHO classification of tumors of haematopoietic and lymphoid tissues. Revised 4th edition. IARC Press, 2017.
- Swerdlow SH, Campo E, Harris NL, et al. (eds). WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon, France: IARC, 2008.
- Dalla Favera R, Bregni M, Erikson J, Patterson J, Gallo RC, Wong-Staal F. Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 1982;79(24):7824-7. DOI: 10.1073/pnas.79.24.7824.
- Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 2012;44(12):1321-5. DOI: 10.1038/ng.2468.
- Kelly GL, Rickinson AB. Burkitt lymphoma: revisiting the pathogenesis of a virus-associated malignancy. Hematology Am Soc Hematol Educ Program 2007;277-84. DOI: 10.1182/asheducation-2007.1.277.
- Shiramizu B, Barriga F, Neequaye J, et al. Patterns of chromosomal breakpoint locations in Burkitt’s lymphoma: relevance to geography and Epstein-Barr virus association. Blood 1991;77:1516-26.
- Mbulaiteye SM, Biggar RJ, Bhatia K, Linet MS, Devesa SS. Sporadic childhood Burkitt lymphoma incidence in United States during 1992-2005. Pediatric Blood and Cancer 2009;53:366-70. DOI: 10.1002/pbc.22047.
- Magrath IT. African Burkitt’s lymphoma. History, biology, clinical features, and treatment. Am J Pediatr Hematol Oncol 1991;13:222-46.
- Pillon M, Mussolin L, Carraro E, et al. Detection of prognostic factors in children and adolescents with Burkitt and diffuse large B-cell lymphoma treated with the AIEOP LNH-97 protocol. Br J Haematol 2016;175(3):467-475. DOI: 10.1111/bjh.14240.
- Murpy SB. Classification, staging and results of treatment of childhood non-Hodgkin’s lymphomas: dissimilarities from lymphomas in adults. Semin Oncol 1980;7:332-39.
- Rosolen A, Perkins SL, Pinkerton R, et al. Revised international pediatric non-Hodgkin lymphoma staging system. Journal of Clinical Oncology 2015;33(18):2112-20. DOI: 10.1200/JCO.2014.59.7203.
- Reiter A, Schrappe M, Tienmann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 1999;94(10):3294-306.
- Woessmann W, Seidemann K, Mann G, et al. The impact of methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood 2005;105:948-58. DOI: 10.1182/blood-2004-03-0973.
- Cairo MS, Gerrard M, Sposto R, et al. Results of randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007;109:2736-43. DOI: 10.1182/blood-2006-07-036665.
- Minard-Colin V, Brugieres L, Reiter A, et al. Non Hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead. Journal of Clinical Oncology 2015;33:2963-74. DOI: 10.1200/JCO.2014.59.5827.
- Cairo MS, Pinkerton R. Childhood, adolescent and young adult non-Hodgkin lymphoma: state of the science. Br J Haematol 2016;173(4):507-30. DOI: 10.1111/bjh.14035.
- Egan G, Goldman S, Alexander S. Mature B-NHL in children, adolescent and young adults: current therapeutic approach and emerging treatment strategies. Br J Haematol 2019;185(6):1071-1085. DOI: 10.1111/bjh.15734.
- Minard-Colin V, Auperin A, Pillon M, et al. Results of the randomized Intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen. Journal of Clinical Oncology 2016;34:10507. DOI: 10.1200/JCO.2016.34.15_suppl.10507.
- Mussolin L, Lovisa F, Gallingani I, et al. Minimal residual disease analysis in childhood mature B-cell leukaemia/lymphoma treated with AIEOP LNH-97 protocol with/without anti-CD20 administration. Br J Haematol 2020;189(3):e108-11. DOI: 10.1111/bjh.16531.
- Anoop P, Sankpal S, Stiller C, et al. Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia. Leuk Lymphoma 2012;53:1882-88. DOI: 10.3109/10428194.2012.677534.
- Jourdain A, Auperin A, Minard-Colin V, et al. Outcome and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective “Lymphomes Malins B” protocols. A Societé Francaise des Cancers de l’Enfant study. Haematologica 2015;100(6):810-7. DOI: 10.3324/haematol.2014.121434.
- Griffin TC, Weitzman S, Weinstein H, et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2009;52(2):177-81. DOI: 10.1002/pbc.21753.
- Giulino-Roth L, Ricafort R, Kernan NA, et al. Ten-year follow up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation. Pediatr Blood Cancer 2013;60(12):2018-24. DOI: 10.1002/pbc.24722.
- Rivers J, Annesley C, Summers C, et al. Early response data for pediatric patients with non-Hodgkin lymphoma treated with CD19 chimeric antigen receptor (CAR) T-cells. Blood 2018;132 (Supplement 1):2957. DOI: 10.1182/blood-2018-99-113744.
- Tolani B, Gopalakrishnan R, Punj V, Matta H, Chaudhary PM. Targeting MYC in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors. Oncogene 2014;33(22):2928-37. DOI: 10.1038/onc.2013.242.
- Bhadury J, Nilsson LM, Veppil Muralidharan S, et al. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proc Natl Acad Sci USA 2014;111(26):E2721-30. DOI: 10.1073/pnas.1406722111.
- Gupta H, Davidoff AM, Pui CH, Shochat SJ, Sandlund JT. Clinical implications and surgical management of intussusception in pediatric patients with Burkitt lymphoma. J Pediatr Surg 2007;42(6):998-1001; discussion 1001. DOI: 10.1016/j.jpedsurg.2007.01.033.
- Wayne ER, Campbell JB, Kosloske AM, Burrington JD. Intussusception in the older child- suspect lymphosarcoma. J Pediatr Surg 1976;11(5):789-94. DOI: 10.1016/0022-3468(76)90104-4.
- Kulendran K, Choy KT, Keogh C, Ratnapala D. An Exceptional Case of Ileocolic Intussusception Secondary to Burkitt’s Lymphoma: What Variations Are There in the Presentation and Management of Those Patients Who Approach Adolescence? Case Rep Surg 2018;2018:6251321. DOI: 10.1155/2018/6251321.
- Mimery AH, Jabbour J, Sykes B, MacDermid E, Al-Askari M, De Clercq S. Burkitt leukemia presenting as acute appendicitis: a case report and literature review. Am J Case Rep 2020;21:e921568. DOI: 10.12659/AJCR.921568.
- Gatta G, Botta L, Rossi S, et al.; EUROCARE Working Group. Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5 - a population-based study. Lancet Oncol 2014;15(1):35-47. DOI: 10.1016/S1470-2045(13)70548-5.
- Michel G, Mulder RL, van der Pal HJH, et al. Evidence-based recommendations for the organization of long-term follow-up care for childhood and adolescent cancer survivors: a report from the PanCareSurFup Guidelines Working Group. J Cancer Surviv 2019;13(5):759-72. DOI: 10.1007/s11764-019-00795-5.
- Jankovic M, Haupt R, Spinetta JJ, et al., participants in PanCare. Long-term survivors of childhood cancer: cure and care-the Erice Statement (2006) revised after 10 years (2016) . J Cancer Surviv 2018;12(5):647-50. DOI: 10.1007/s11764-018-0701-0.
- Jankovic M, Fraschini D, Nova G. Ragazzi guariti da tumore pediatrico: una realtà in continua crescita. Quaderni acp 2019;2:67-73.
- Gupta A, Moore JA. Tumor lysis syndrome. JAMA Oncol 2018;4(6):895. DOI: 10.1001/jamaoncol.2018.0613.
- Rahmani B, Patel S, Seyam O, et al. Current understanding of tumor lysis syndrome. Hematol Oncol 2019;37(5):537-47. DOI: 10.1002/hon.2668.
- Wössmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A. Incidence of tumor lysis syndrome in children with advanced stage Burkitt’s lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol 2003;82(3):160-5. DOI: 10.1007/s00277-003-0608-2.
- Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014;32(27):3048-58. DOI: 10.1200/JCO.2013.53.5229.
- Karantanis D, Durski JM, Lowe VJ, et al. 18F-FDG PET and PET/CT in Burkitt’s lymphoma. Eur J Radiol 2010;75(1):e68-73. DOI: 10.1016/j.ejrad.2009.07.035.
- Sandlund JT. Burkitt lymphoma: staging and response evaluation. Br J Haematol 2012;56(6):761-5. DOI: 10.1111/j.1365-2141.2012.09026.x.
- Bailly C, Eugène T, Couec ML, et al. Prognostic value and clinical impact of (18)FDG-PET in the management of children with Burkitt lymphoma after induction chemotherapy. Front Med (Lausanne) 2014;1:54. DOI: 10.3389/fmed.2014.00054.
- Furth C, Steffen IG, Erdrich AS, et al. Explorative analyses on the value of interim PET for prediction of response in pediatric and adolescent non-Hodgkin lymphoma patients. EJNMMI Res 2013;3(1):71. DOI: 10.1186/2191-219X-3-71.
- Riad R, Omar W, Sidhom I, et al. False-positive F-18 FDG uptake in PET/CT studies in pediatric patients with abdominal Burkitt’s lymphoma. Nucl Med Commun 2010;31(3):232-8. DOI: 10.1097/MNM.0b013e328334fc14.
- Carrillo-Cruz E, Marín-Oyaga VA, Solé Rodríguez M, et al. Role of 18F-FDG-PET/CT in the management of Burkitt lymphoma. Eur J Haematol 2015;94(1):23-30. DOI: 10.1111/ejh.12284.